Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Evaluation of tofacitinib in cutaneous sarcoidosis [Olink Explore 1536]
PubMed Full text in PMC Similar studies Analyze with GEO2R
Olink Human Proximity Extension Assay Explore 1536
Healthy control 11 [Olink Explore 1536 panel]
Healthy control 10 [Olink Explore 1536 panel]
Healthy control 9 [Olink Explore 1536 panel]
Healthy control 8 [Olink Explore 1536 panel]
Healthy control 7 [Olink Explore 1536 panel]
Healthy control 6 [Olink Explore 1536 panel]
Healthy control 5 [Olink Explore 1536 panel]
Healthy control 4 [Olink Explore 1536 panel]
Healthy control 3 [Olink Explore 1536 panel]
Healthy control 2 [Olink Explore 1536 panel]
Healthy control 1 [Olink Explore 1536 panel]
Sarcoidosis patient 3 treated with 15 mg tofacitinib [Olink Explore 1536 panel]
Sarcoidosis patient 1 treated with 5 mg tofacitinib [Olink Explore 1536 panel]
Sarcoidosis patient 10 after treated with tofacitinib for six months [Olink Explore 1536 panel]
Sarcoidosis patient 10 prior to treated with tofacitinib [Olink Explore 1536 panel]
Sarcoidosis patient 8 after treated with tofacitinib for six months [Olink Explore 1536 panel]
Sarcoidosis patient 8 prior to treated with tofacitinib [Olink Explore 1536 panel]
Sarcoidosis patient 7 after treated with tofacitinib for six months [Olink Explore 1536 panel]
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on